Rebekah Jordan

EPM's Rebekah Jordan and Med-Tech Innovation's Ian Bolland are joined by Richard Williams from Healome Therapeutics to discuss the challenges of going from a university spin-out to a successful company.

Editor Rebekah Jordan spoke to Honeywell to explore its long-term supply agreement with DevPro Biopharma to develop a respiratory inhaler that enhances the well-being of patients.

Editor Rebekah Jordan spoke to Kevin Kreutter, Ph.D., senior vice president, Drug Discovery, Empress Therapeutics about how the company is using AI to analyse genetic data, to accelerate and refine small molecule drug discovery.

Avantor has opened its new flagship Bridgewater Innovation Center, adding to Avantor’s network of 13 research and innovation centres across the globe.

Editor Rebekah Jordan speaks to Ivan Wall, a professor at the University of Birmingham and co-director of the Resilience project, to learn about the advancements the initiative is making in UK medicines manufacturing.

The NHS England is rolling out a new and improved pill to help people stop smoking, giving thousands of smokers a better chance to quit for good.

Infinitopes’ lead vaccine candidate ITOP1 is a novel, precision targeted “off-the-shelf” cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers.

iotaSciences announced the upcoming launch of its newly developed Single-Cell Cloning Platform XT at the Cell 2024 event in London (UK) from November 6-8, 2024.

Lonza's Synaffix collaborates with BigHat Biosciences for the development of a machine learning-designed ADC.

Berry Global has launched a new easy-squeeze ophthalmic 10ml bottle that has been qualified for use with Aptar Pharma’s globally recognised Ophthalmic Squeeze Dispenser (OSD).

Terumo advances adoption of automated manufacturing to bring novel cell and gene therapies to more Latin American patients.

Takeda announced positive interim results from a Phase 3-enabling proof-of-concept study for mezagitamab (TAK-079), an anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN).

The FDA has expanded approval for Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to include adults aged 18–59 years who are at higher risk of lower respiratory tract disease from the virus due to chronic conditions.

The study will offer whole genome sequencing to newborns using their blood samples to test for over 200 rare genetic conditions.

Patients receiving treatment for bowel cancer at Sheffield Teaching Hospitals NHS Foundation Trust will have the chance to try personalised 'vaccines' thanks to the launch of a NHS “matchmaking” service.

Johnson & Johnson (J&J) has announced that it has taken over all sales, marketing, and distribution responsibilities for Remicade (infliximab) and Simponi (golimumab) in the UK.

Shionogi & Co., Ltd. shared new data at IDWeek 2024 from the PROVE study, the largest global real-world evidence review of Fetroja/Fetcroja (cefiderocol).

Veranova announced the appointment of two distinguished industry leaders, Dr. Rajni Aneja and Dr. Bradley L. Pentelute, to its advisory board.

medac group reported a series of productive and insightful meetings with both current and potential business partners during this year’s CPHI Congress in Milan.

The results showed that Ellorarxine significantly increases MAP2 expression at remarkably low concentrations (10nM), induces neurite outgrowth, increases mitochondrial viability to combat oxidative stress, ameliorates neuroinflammation and modifies G